CPI-1189. Centaur.

Abstract

The efficacy of the proapoptotic cytokine tumor necrosis factor (TNF) alpha-inhibiting compound CPI-1189 has been demonstrated in various cell culture and animal models of chronic neurodegenerative and inflammatory diseases. CPI-1189 intracellularly inhibits the p38 mitogen-activated protein kinase phosphoactivation, thereby protecting against TNF alpha-induced neurodegeneration. Clinical proof-of-concept phase IIa trials in patients with Parkinson's disease and AIDS dementia complex were successful. These studies demonstrated clinical relevance for treatment with CPI-1189 (50 to 100 mg/day), which attenuated the deterioration in cognitive and/or motor function without any relevant side effects. Since the importance of neuroprotection is emerging, in particular in neurodegenerative diseases with concomitant observed immunological pro-apoptotic alterations in the central nervous system, long-term application of CPI-1189 could represent a promising future therapeutic alternative, in addition to neuroprotective compounds such as selegiline.

• Authors: Thomas Müller
• Journal: Current opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 3 Issue 12 Pg. 1763-7 (Dec 2002) ISSN: 1472-4472 [Print] England
• PMID: 12528314 (Publication Type: Journal Article, Review)

Chemical References

• Butanes
• Nitrogen Oxides
• CPI 1189

Topics

• Animals
• Butanes (chemistry, pharmacology, therapeutic use)
• Clinical Trials as Topic (statistics & numerical data)
• Drug Industry (legislation & jurisprudence, methods)
• Humans
• Neurodegenerative Diseases (drug therapy)
• Nitrogen Oxides (chemistry, pharmacology, therapeutic use)